Background: Acidic inhalers can be associated with increased adverse reactions. Objectives: This study aimed to determine the acute local tolerability of acidic aqueous placebo formulations delivered via Respimat® Soft Mist™ Inhaler (SMI) and placebo chlorofluorocarbon metered dose inhaler (CFC-MDI).Methods: A single-dose (four inhalations), randomized, double-blind within Respimat SMI device, four-way crossover study in asthma patients with documented bronchial hyperresponsiveness was used. Patients received acidic placebo solutions [pH 2.7, 3.4 or 7.0 (neutral)], delivered via Respimat SMI or placebo CFC-MDI. The primary endpoint was the largest decrease in forced expiratory volume in 1 s (FEV1) from baseline to 0–30 min after dosing. Secondary endpoints included spirometry, paradoxical bronchoconstriction (defined as a fall in FEV1 ≧15% below baseline within 30 min of dosing), cough episodes and adverse events.Results: Thirty-two patients were included in the per-protocol population (mean age 27 years, 62.5% males). The mean percentage decrease in FEV1 was comparable between treatment groups: –1.6% (Respimat SMI pH 2.7), –1.8% (Respimat SMI pH 7.0), –1.9% (CFC-MDI), and –2.3% (Respimat SMI pH 3.4); no patient experienced paradoxical bronchoconstriction. The mean number of cough episodes was significantly lower in the Respimat SMI pH 2.7 group versus CFC-MDI (p = 0.0165). No patient used rescue medication. Only 3 patients experienced at least one adverse event. Conclusions: The Respimat SMI pH 2.7 placebo solution does not induce adverse events in these patients. Compared with the CFC-MDI placebo suspension, Respimat SMI is a well-tolerated inhaled medication delivery system that can accommodate medication formulations with a wide range of pH solutions.

Keywords:
Tiotropium, Respimat® Soft Mist™ Inhaler, Forced expiratory volume in 1 s, Chronic obstructive pulmonary disease
1.
Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B: Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996;85:960–964.
2.
Steed KP, Towsle LJ, Freund B, Newman SP: Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser. Eur J Pharm Sci 1997;5:55–61.
3.
Newman SP, Brown J, Steed KP, Reader SJ, Kladders H: Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957–963.
4.
Pitcairn G, Reader S, Pavia D, Newman S: Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005;18:264–272.
5.
Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ, Dutch/Belgian Tiotropium Study Group: Improved health outcomes in patients with COPD during 1-year treatment with tiotropium. Eur Respir J 2002;19:209–216.
6.
Olin JL: Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease. Am J Health Syst Pharm 2005;62:1263–1269.
7.
Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–224.
8.
O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832–840.
9.
Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, Le Merre C, Iacono P, Huchon G: The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420–427.
10.
Matera MG, Sanduzzi A, Ponticiello A, Vatrella A, Salzillo A, Cazzola M: An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration 2005;72:466–470.
11.
Ricciardolo FL, Gaston B, Hunt J: Acid stress in the pathology of asthma. J Allergy Clin Immunol 2004;113:610–619.
12.
Schmidt D, Jorres RA, Magnussen H: Citric acid-induced cough thresholds in normal subjects, patients with bronchial asthma, and smokers. Eur J Med Res 1997;2:384–388.
13.
Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A: Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418–424.
14.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.
15.
National Asthma Education and Prevention Program. Clinical Practice Guidelines. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health. Bethesda, Md., National Heart, Lung, and Blood Institute, 1997.
16.
American Thoracic Society: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107–1136.
17.
Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, Beck E: Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat® soft mist™ inhaler. Respir Med 2005;99:1087–1095.
18.
Koehler D, Pavia D, Dewberry H, Hodder R: Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat® Soft Mist™ inhaler: results of phase II single-dose crossover studies. Respiration 2004;71:469–476.
19.
Patel KR, Pavia D, Lowe L, Spiteri M: Inhaled ethanolic and aqueous solutions via Respimat®Soft Mist™ Inhaler are well-tolerated in asthma patients. Respiration 2006;73:434–440.
20.
Ricciardolo FL: Mechanisms of citric acid-induced bronchoconstriction. Am J Med 2001;111:18S–24S.
21.
Hunt J: Airway acidification: interactions with nitrogen oxides and airway inflammation. Curr Allergy Asthma Rep 2006;6:47–52.
22.
Yagi Y, Kuwahara M, Nanji A, Birumachi J-I, Nishibata R, Mikami H, Tsubone H: The difference in citric acid-induced cough in congenitally bronchial-hypersensitive (BHS) and bronchial-hyposensitive (BHR) guinea pigs. Exp Anim 2001;50:371–378.
23.
Borrill Z, Starkey C, Vestbo J, Singh D: Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. Eur Respir J 2005;25:269–274.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.